Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Alberto Blanco, Ajai Chari, Thomas G Martin, Shagun Arora, Alfred Chung, Anupama Deepa Kumar, Nina Shah, Sandy W. Wong, Hiroyuki Takamatsu, Joaquin Martínez-López, Jeffrey Lee Wolf

Blood (2024) 144 (Supplement 1): 7020.

https://doi.org/10.1182/blood-2024-203768

Published: 2024

Journal Articles

Using Next Generation Sequencing to Identify Trackable Clonotypic Sequences for Minimal Residual Disease Testing in AL Amyloidosis

Xia Wu, Ping Zhou, Sandy W. Wong, Benjamin Rosenthal, Alfred Chung, Denis Toskic, Stephanie Scalia, Raymond Comenzo

Blood (2023) 142 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2023-190355

Published: 2023

Journal Articles

Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Natasha S Bahri, Alfred Chung, Chiung-Yu Huang, Shagun Arora, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Moming Li, Sandy W. Wong

Blood (2022) 140 (Supplement 1): 4285–4286.

https://doi.org/10.1182/blood-2022-167281

Published: 2022

Journal Articles

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer

Blood (2022) 140 (Supplement 1): 394–396.

https://doi.org/10.1182/blood-2022-159711

Published: 2022

Journal Articles

A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Sireesha Asoori, Alfred Chung, Nina Shah, Shagun Arora, Jeffrey L. Wolf, Thomas Martin, Sandy W. Wong

Blood (2022) 140 (Supplement 1): 7233–7234.

https://doi.org/10.1182/blood-2022-168451

Published: 2022

Journal Articles

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Kelsey H. Natsuhara, Chiung-Yu Huang, Jennifer Knoche, Shagun Arora, Alfred Chung, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 7910–7912.

https://doi.org/10.1182/blood-2022-155906

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Ping Zhou, Mahesh M Mansukhani, Denis Toskic, Stephanie Scalia, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10048–10049.

https://doi.org/10.1182/blood-2022-157790

Published: 2022

Journal Articles

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Kevin R. Reyes, Chiung-Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5105–5107.

https://doi.org/10.1182/blood-2022-160362

Published: 2022

Journal Articles

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Alfred Chung, Chiung-Yu Huang, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah

Blood (2022) 140 (Supplement 1): 12651–12652.

https://doi.org/10.1182/blood-2022-170744

Published: 2022

Journal Articles

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Stephanie Scalia, Denis Toskic, Ping Zhou, Mahesh M Mansukhani, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10120–10121.

https://doi.org/10.1182/blood-2022-162352

Published: 2022

Journal Articles

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Isaac W. Boss, Ethan Thompson, Allison M. Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 7116–7117.

https://doi.org/10.1182/blood-2022-163192

Published: 2022

Journal Articles

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Aneeqa A Zafar, Chiung-Yu Huang, Mimi Lo, Jen Knoche, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5218–5220.

https://doi.org/10.1182/blood-2022-162122

Published: 2022

Journal Articles

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Kevin R Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin, Nina Shah, Sandy W. Wong, Jeffrey L. Wolf, Shagun Arora, Alfred Chung

Blood (2022) 140 (Supplement 1): 617–619.

https://doi.org/10.1182/blood-2022-160401

Published: 2022

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation

Rahul Banerjee, Ann A. Lazar, Chloe Ryan, Jen Knoche, Kelly Jean Brassil, Lindsey Jackson, Dhiren Patel, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Anand Dhruva, Nina Shah

Blood (2021) 138 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2021-147125

Published: 2021

Journal Articles

Impact of Corticosteroids on Efficacy of BCMA Targeted CAR-T Therapy in Multiple Myeloma

Eva Duvalyan, Mimi Lo, Thomas Martin, Jeffrey L. Wolf, Alfred Chung, Shagun Arora, Nina Shah, Chiung-Yu Huang, Sandy W. Wong

Blood (2021) 138 (Supplement 1): 1759.

https://doi.org/10.1182/blood-2021-146678

Published: 2021

Journal Articles

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

Sandy W. Wong, Shambavi Richard, Yi Lin, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Vadim Romanov, Michael Trigg, Martin Vogel, Ashraf Garrett, Lisa Hullinger, Tonia Nesheiwat, Thomas Martin, Sundar Jagannath

Blood (2021) 138 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2021-150592

Published: 2021

Journal Articles

Feasibility of a Supportive Mobile Health App for Chimeric Antigen Receptor T-Cell Therapy

Rahul Banerjee, Bella Sykes, Nina Shah, Charalambos Andreadis, Peter H. Sayre, Thomas Martin, Jason Shore, Adam Sodowick, Sandy W. Wong

Blood (2021) 138 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2021-147131

Published: 2021

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

NARROW

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Using Next Generation Sequencing to Identify Trackable Clonotypic Sequences for Minimal Residual Disease Testing in AL Amyloidosis

Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation

Impact of Corticosteroids on Efficacy of BCMA Targeted CAR-T Therapy in Multiple Myeloma

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

Feasibility of a Supportive Mobile Health App for Chimeric Antigen Receptor T-Cell Therapy

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only